Entering text into the input field will update the search result below

XBiotech completes enrollment in Phase 2 study evaluating bermekimab in patients with atopic dermatitis

Oct. 05, 2018 8:24 AM ETXBiotech Inc. (XBIT) StockBy: SA News Team
  • XBiotech (NASDAQ:XBIT) has completed enrollment in its Phase 2, open label clinical study evaluating subcutaneous administration of bermekimab in patients with moderate to severe Atopic Dermatitis (AD).
  • The Phase 2 study consists of two dose cohorts. Nine patients in the first dosing cohort received a total of 4 weekly 200mg injections of bermekimab followed by safety assessments. Patients in the second cohort will receive 8 weekly 400mg injections of bermekimab for assessment of safety and preliminary efficacy.
  • XBiotech has now exceeded enrollment in the final cohort of patients.

Recommended For You

More Trending News

About XBIT Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
XBIT--
XBiotech Inc.